Polycythemia Vera Therapeutics Market, by Disease Type (Primary Polycythemia Vera and Secondary Polycythemia Vera), by Drug Class (Antimetabolite, Kinase Inhibitors, Alpha Interferon, Selective Serotonin Reuptake Inhibitors, and Others), by Route of Admin

Polycythemia Vera Therapeutics Market, by Disease Type (Primary Polycythemia Vera and Secondary Polycythemia Vera), by Drug Class (Antimetabolite, Kinase Inhibitors, Alpha Interferon, Selective Serotonin Reuptake Inhibitors, and Others), by Route of Administration (Oral, Intravenous, Intramuscular, and Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Polycythemia vera is a blood disorder in which the body creates too many red blood cells. These extra red cells make blood thicker than normal. The thickened blood flows slower and may clot within body. Red blood cells carry oxygen to organs and tissues throughout the body. If the blood moves too slowly or clots, the cells cannot deliver enough oxygen. This situation can cause serious complications including heart attack, stroke, and heart failure. There are two types of polycythemia vera, which include primary polycythemia vera and secondary polycythemia vera. Polycythemia vera gets worse with time if remain undiagnosed and can be life-threatening. Polycythemia vera can be treatable but is not curable. Polycythemia vera treatment may include phlebotomy and drug therapy. Phlebotomy involves the removal of blood from the body. Drug therapy involves the use of Hydroxyurea and Interferon-alfa. Patients who do not respond to hydroxyurea are treated with ruxolitinib (jakafi) or busulfan. At times a low dose of aspirin, allopurinol and antihistamines are also preferred for polycythemia vera treatment. Givinostat is an emerging drug in global polycythemia vera treatment market.
Market Dynamics
The increasing incidence of polycythemia vera, rising research and development activities for the development of novel therapeutics for the treatment of polycythemia vera, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global polycythemia vera therapeutics market over the forecast period.
For instance, according to the National Organization for Rare Disorders, polycythemia vera affects slightly more men than women and the disorder is estimated to affect around 44 to 57 per 100,000 people in the U.S. each year It occurs most often in individuals over 60 years old, but can affect individuals of any age. It is extremely rare in individuals under the age of 20.
Key features of the study:
This report provides in-depth analysis of the global polycythemia vera therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global polycythemia vera therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Pfizer Inc, Galena Biopharma, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, PharmaEssentia Corporation, Bayer AG, Mylan N.V., Teva Pharmaceuticals Industries Ltd, GlaxosmithKline plc, ANP Technologies, INC., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc, Karus Therapeutics Limited, and Miragen Therapeutics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global polycythemia vera therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global polycythemia vera therapeutics market
Detailed Segmentation:
Global Polycythemia Vera Therapeutics Market, By Disease Type:
Primary Polycythemia Vera
Secondary Polycythemia Vera
Global Polycythemia Vera Therapeutics Market, By Drug Class:
Antimetabolite
Kinase Inhibitors
Alpha Interferon
Selective Serotonin Reuptake Inhibitors
Others
Global Polycythemia Vera Therapeutics Market, By Route of Administration:
Oral
Intravenous
Intramuscular
Subcutaneous
Global Polycythemia Vera Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Polycythemia Vera Therapeutics Market, By Region:
North America
By Disease Type
Primary Polycythemia Vera
Secondary Polycythemia Vera
By Drug Class
Antimetabolite
Kinase Inhibitors
Alpha Interferon
Selective Serotonin Reuptake Inhibitors
Others
By Route of Administration
Oral
Intravenous
Intramuscular
Subcutaneous
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Disease Type
Primary Polycythemia Vera
Secondary Polycythemia Vera
By Drug Class
Antimetabolite
Kinase Inhibitors
Alpha Interferon
Selective Serotonin Reuptake Inhibitors
Others
By Route of Administration
Oral
Intravenous
Intramuscular
Subcutaneous
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Disease Type
Primary Polycythemia Vera
Secondary Polycythemia Vera
By Drug Class
Antimetabolite
Kinase Inhibitors
Alpha Interferon
Selective Serotonin Reuptake Inhibitors
Others
By Route of Administration
Oral
Intravenous
Intramuscular
Subcutaneous
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Disease Type
Primary Polycythemia Vera
Secondary Polycythemia Vera
By Drug Class
Antimetabolite
Kinase Inhibitors
Alpha Interferon
Selective Serotonin Reuptake Inhibitors
Others
By Route of Administration
Oral
Intravenous
Intramuscular
Subcutaneous
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Disease Type
Primary Polycythemia Vera
Secondary Polycythemia Vera
By Drug Class
Antimetabolite
Kinase Inhibitors
Alpha Interferon
Selective Serotonin Reuptake Inhibitors
Others
By Route of Administration
Oral
Intravenous
Intramuscular
Subcutaneous
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Disease Type
Primary Polycythemia Vera
Secondary Polycythemia Vera
By Drug Class
Antimetabolite
Kinase Inhibitors
Alpha Interferon
Selective Serotonin Reuptake Inhibitors
Others
By Route of Administration
Oral
Intravenous
Intramuscular
Subcutaneous
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Pfizer Inc *
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Galena Biopharma
Bristol-Myers Squibb Company
Novartis AG
Eli Lilly and Company
PharmaEssentia Corporation
Bayer AG
Mylan N.V.
Teva Pharmaceuticals Industries Ltd
GlaxosmithKline plc
ANP Technologies, INC.
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc
Karus Therapeutics Limited
Miragen Therapeutics, Inc.
“*” marked represents similar segmentation in other categories in the respective section.